We have a new contact lens!

Something to watch: a potential treatment option for retinitis pigmentosa.

Aldeyra Therapeutics announced that the FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP).

Tell me more.

Dihydrofolate reductase is an enzyme involved in cellular replication and activation. Methotrexate, the active component of ADX-2191, is a dihydrofolate reductase inhibitor that has been used to treat cancer and autoimmune disease.

In addition to RP, the FDA has granted orphan drug designation to ADX-2191 for the treatment of primary vitreoretinal lymphoma, a rare, aggressive, high-grade cancer. The drug also received orphan drug designation and fast track designation for the prevention of proliferative vitreoretinopathy, which is the leading cause of retinal reattachment surgery failure.

Stay tuned. (via)


WHAT YOUR PATIENT MIGHT ASK YOU

Are there any new monthly contact lenses?

Yes! TOTAL30 (Alcon) is the newest member of the Water Gradient family, designed for monthly lens wearers.

Tell me more.

The reusable, Water Gradient design of TOTAL30 is made possible by the introduction of new biomimetic CELLIGENT Technology, which combines a biomimetic surface and a unique lens chemistry to help resist bacteria and lipid deposits. The lens features an inherently lubricious surface that is as soft as the human cornea, according to Alcon. The Water Gradient surface of TOTAL30 is durable and remains intact during a full month of wear with daily cleaning, disinfecting, and storing. It is compatible with all lens care solutions.

Is there a toric option?

Not yet. Right now TOTAL30 is available in sphere powers only with a power range from -12.00 through +8.00.

When can we get this?

The lens will be available next month. (via)


Source:

Modern Optometry

By Marion Evans